Cidara Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Cidara Therapeutics has a total shareholder equity of $115.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $162.3M and $46.7M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$127.39m
Equity	US$115.63m
Total liabilities	US$46.70m
Total assets	US$162.33m

Recent financial health updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

Financial Position Analysis

Short Term Liabilities: CDTX's short term assets ($156.8M) exceed its short term liabilities ($44.3M).

Long Term Liabilities: CDTX's short term assets ($156.8M) exceed its long term liabilities ($2.4M).

Debt to Equity History and Analysis

Debt Level: CDTX is debt free.

Reducing Debt: CDTX has no debt compared to 5 years ago when its debt to equity ratio was 20.3%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CDTX has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: CDTX has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 7% each year.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 13:45
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cidara Therapeutics, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Timothy Chiang	BTIG
Chiara Russo	Cantor Fitzgerald & Co.
Louise Chen	Cantor Fitzgerald & Co.

Cidara Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

Cidara Therapeutics, Inc. Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors

Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members

Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388

Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

Consensus estimates of losses per share improve by 21%

New minor risk - Profitability

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

New major risk - Financial position

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

Consensus revenue estimates fall by 30%

New minor risk - Profitability

Forecast to breakeven in 2025

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection)

Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

New minor risk - Market cap size

Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform

Consensus revenue estimates increase by 85%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS misses analyst expectations

Forecast to breakeven in 2023

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Price target decreased to US$5.50

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform

Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

High number of new directors

Consensus revenue estimates increase by 67%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market

Cidara spikes on $11M milestone payment from partner Mundipharma

Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Cidara Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.67

High number of new directors

Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

Cidara Therapeutics, Inc. Announces Executive Changes

Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

Consensus revenue estimates increase by 44%

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Medicines and Healthcare Products Regulatory Agency in the UK Grants Mundipharma and Cidara Therapeutics Inc.'s Rezafungin Promising Innovative Medicine Designation

Cidara Therapeutics, Inc. Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Price target increased to US$6.25